Skip to main content

Healthy Male

6
Pipeline Programs
7
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Hyundai Pharmaceutical Co
2 programs
2
Choline CR 600mgPhase 11 trial
Surfolase capsulePhase 11 trial
Active Trials
NCT02395926Completed24Est. Dec 2013
NCT02395913Completed72Est. Sep 2013
NGM Biopharmaceuticals
1 program
1
AldaferminPhase 11 trial
Active Trials
NCT04828265Completed36Est. Jul 2021
InventisBio
InventisBioChina - Shanghai
1 program
1
D-1553Phase 11 trial
Active Trials
NCT06105255Completed45Est. Feb 2024
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
TC-5214Phase 11 trial
Active Trials
NCT01359618Terminated16Est. Apr 2012
Prevail Therapeutics
1 program
1
[14C]-LY3549492Phase 1
GC Biopharma
GC BiopharmaKorea - Yongin
1 program
GCC-4401PHASE_11 trial
Active Trials
NCT01651234Completed48Est. Aug 2012
Idience
IdienceCA - San Francisco
1 program
IDX-1197PHASE_11 trial
Active Trials
NCT05202912Completed37Est. Jul 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
InventisBioD-1553
IdienceIDX-1197
NGM BiopharmaceuticalsAldafermin
Hyundai Pharmaceutical CoCholine CR 600mg
Hyundai Pharmaceutical CoSurfolase capsule
GC BiopharmaGCC-4401
AstraZenecaTC-5214

Clinical Trials (7)

Total enrollment: 278 patients across 7 trials

NCT06105255InventisBioD-1553

A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553

Start: May 2023Est. completion: Feb 202445 patients
Phase 1Completed
NCT05202912IdienceIDX-1197

Food Effect Study of IDX-1197 in Healthy Subjects

Start: Jan 2022Est. completion: Jul 202237 patients
Phase 1Completed
NCT04828265NGM BiopharmaceuticalsAldafermin

Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

Start: Apr 2021Est. completion: Jul 202136 patients
Phase 1Completed
NCT02395926Hyundai Pharmaceutical CoCholine CR 600mg

To Evaluate Safety and the Pharmacokinetic Characteristics After Oral Administration of HT-003 Compared With Choline Alfoscerate Capsule in Healthy Adult Male Volunteers

Start: Oct 2013Est. completion: Dec 201324 patients
Phase 1Completed
NCT02395913Hyundai Pharmaceutical CoSurfolase capsule

Compare Safety and Pharmacokinetic Properties of Surfolase Capsule(Acebrophylline 100mg) and Surfolase CR(200mg)

Start: Jul 2013Est. completion: Sep 201372 patients
Phase 1Completed
NCT01651234GC BiopharmaGCC-4401

A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy Volunteers

Start: Mar 2012Est. completion: Aug 201248 patients
Phase 1Completed
NCT01359618AstraZenecaTC-5214

Determining Highest Dose Administration of TC-5214 and Evaluating Effect on the Electrical Activity in the Heart

Start: Jun 2011Est. completion: Apr 201216 patients
Phase 1Terminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.